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ABSTRACT
Background: There are few reports on the effects of intranasal Botulinum Toxin-A (BTX-A) as a treatment of
allergic rhinitis (AR). In this study, we compared the efficacy of intranasal BTX-A to cetirizine in the treatment of
AR.
Methods: Fifty AR patients at the age of 26.2 ± 9.1 years (64% females), were recruited to the trial according
to the Allergic Rhinitis and its Impact on Asthma (ARIA) criteria. Participants randomly received either intrana-
sal injection of BTX-A (75 IU DysportⓇ) or cetirizine (10 mgday). Symptoms (based on the ARIA) and side ef-
fects were assessed every two weeks for two months. Quality of life was evaluated before and after the study
using the Rhinasthma questionnaire.
Results: Total symptom severity score of patients significantly decreased (P < 0.001) and quality of life signifi-
cantly improved (P < 0.001) at the same level in both groups. Side effects included nasal dryness (4%) and
epistaxis (4%) in the BTX-A group. In the cetirizine group 44% sleepiness and 4% blurred vision was reported.
Conclusions: Nasal injection of BTX-A shows the same therapeutic effects as cetirizine in the management
of AR. Since BTX is expensive, we do not suggest it in the first line of treatment for AR. However, BTX-A is a
potential treatment for patients who are resistant or not compliant to the routine medications of AR. Further
studies are required to investigate implications and limitations of BTX-A in the treatment of AR.
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INTRODUCTION
Allergic rhinitis (AR) is a common disease with a
high prevalence of about 24% in Iranian population in
2003.1 The prevalence of AR has increased over the
last decade in several Middle East countries.2 The up-
per respiratory symptoms of AR include nasal con-
gestion, itching, rhinorrhea, and sneezing. These
symptoms are caused by the release of granular-
associated mediators due to the activation of mast
cells residing in nasal tissue. Mast cells of the respira-
tory mucosa and basophiles in the blood coated by
IgE are said to be sensitized. These mechanisms are
responsible for respiratory symptoms after exposure
to the allergen in atopic individuals. There are also
other proposed mechanisms to explain non-allergic
rhinitis including those that are not related to mu-
cosal impairment by inflammation, such as autonomic
imbalance and hyper-responsiveness of the sensory
nerves.3-5
Depending on the pathogenesis of rhinitis and pa-
tient’s complaints, several treatment strategies are
recommended, such as intranasal and systemic corti-
costeroids, histamine H1 antagonists, decongestants,
cromolyn sodium, antileukotrienes, anticholinergics,
capsaicin, anti-IgE agents, and intranasal saline.6
However, the conventional medications are not able
to completely control the symptoms in most of the pa-
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tients. Another limitation to conventional treatments
is side effects associated with medications e.g.
drowsiness with histamine H1 antagonists.
Botulinum toxin (BTX) is a natural neuroparalytic
agent, extracted from the purified toxin of clostridium
botulinum bacteria. There are eight types of BTX
from A to G, with different immunological specificity.7
BTX inhibits the function of acetylcholine in presyn-
aptic area of neuromuscular junctions and conse-
quently blocks the cholinergic pathways.8 Currently
in otolaryngology, BTX is administered to achieve
various therapeutic goals including treatment of spas-
ticity, dystonia, strabismus and other face movement
disorders. Recently, innovative usage of BTX in cos-
metic procedures, pain relief, involuntary muscle con-
tractions and glandular hypersecretion has been sug-
gested.9 Findings by other studies emphasize the effi-
ciency of BTX type A (BTX-A) in the treatment of
rhinitis. Rohrbach et al. demonstrated that BTX-A
sponge (BotoxⓇ) could reduce the symptoms of
rhinitis in individuals resistant to other medications.10
Another study showed that 25 units (IU) of injected
BTX-A (BotoxⓇ) is more effective than injected triam-
cinolone in relieving AR symptoms.11 Also, injection
of 20 IU BTX-A (BotoxⓇ) into each nasal cavity has
been shown to be an appropriate method in control-
ling the symptoms of rhinitis.12 However, with all the
valuable data available, there are still few reports on
the effects of BTX-A and histamine H1 antagonists in
controlling AR symptoms. The aim of this study was
to compare the effects of intranasal BTX-A injection
versus cetirizine administration in relieving the symp-
toms of AR.
METHODS
PATIENTS AND SETTINGS
This randomized, controlled trial was conducted on
patients with AR referred to the outpatient otolaryn-
gology clinics in Alzahra and Kashani university hos-
pitals of Isfahan (Iran), between 2010 and 2012. Diag-
nosis of AR was made by an otorhinolaryngologist
based on a comprehensive assessment of symptoms
and physical examination and according to the Aller-
gic Rhinitis and its Impact on Asthma (ARIA) criteria.
Participants had three upper respiratory symptoms
including sneezing, nasal obstruction and discharge.5
Patients with the history of rhinoplasty, nasal
anatomic abnormality (i.e. nasal polyp or septal devia-
tion), persistent asthma, long use of systemic corti-
costeroids, malignancy, tuberculosis, diabetes melli-
tus and other chronic systemic disease as well as
pregnant females were excluded from the study. Pa-
tients on local corticosteroids at the time of the study
were not included. Calculated sample size was 25
cases in each group with type I error (alpha) of 0.05
and study power of 80%. We expected at least one
score difference between the two groups in ARIA to-
tal score. The ethics committee of the Isfahan Univer-
sity of Medical Sciences approved the study and all
patients signed a consent form before participating in
the trial. The trial has also been registered at Iranian
Registry for Clinical Trials: IRCT201208261579N3.
INTERVENTION
Using random table numbers, patients were ran-
domly assigned into two groups of BTX-A and cetiriz-
ine. In the BTX-A group, participants were treated
with a single dose intranasal injection of BTX-A
(DysportⓇ, Ipsen Biopharm, Wrexham, UK) and the
other group were treated with cetirizine (Abidi Co.,
Tehran, Iran) 10 mg once daily. In the BTX-A group,
the procedure was applied while the patients were in
sitting position. Local intranasal anesthesia was con-
ducted with 10% lidocaine sprayed 10 minutes before
the injection. Each vial of 495 IU BTX-A was diluted
with 3.3 cc of distilled water (150 IUcc), and 0.5 cc
(75 IU each nasal cavity) of this solution was slowly
injected into the anterior part of each inferior tur-
binate via insulin needle.
ASSESSMENTS
Patients were visited every two weeks for two
months. In each visit, questionnaires including symp-
toms and side effects were filled out by the same oto-
laryngologist throughout the study. Clinical symp-
toms were evaluated according to the ARIA criteria.5
The questionnaire in this section evaluated five major
symptoms including sneezing, rhinorrhea, nasal con-
gestion, nasal itching, and eye rednessitchingwa-
teriness. Severity of each symptom was graded from
0 (no symptom) to 3 (severe). Patient’s quality of life
was evaluated before and after the study using the
Rhinasthma questionnaire that is designed to evalu-
ate the quality of life in rhinitisasthma or both and
includes 30 items; each question scored from 0
(none) to 2 (moderate to severe).13
STATISTICAL ANALYSIS
Data were analyzed using the SPSS software for win-
dows version 16.0. Independent sample t-Test and
Chi-square test were used for comparing quantitative
and qualitative variables between the two groups. Re-
peated Measures test was used to analyze the trend
of changes within and between the groups. Multivari-
ate analyses conducted where needed. P value of
<0.05 was considered significant.
RESULTS
During the course of the study, 50 AR patients at the
age of 26.2 ± 9.1 years (64% female) were included
and all of them completed the study. The two groups
were similar with regards to demographic and base-
line clinical variables. Trend of changes in total symp-
tom severity score is presented in Table 1. At the end
of the trial, the total symptom severity score was sig-
nificantly reduced in both groups (P < 0.001). Re-
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Fig.　1　Trend of change in ARIA score during the study.
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Table　1　Symptom severity score from baseline to the end 
of study
Dysport
n = 25
Cetirizine
n = 25 P*
Baseline 10.8 ± 2.4 9.8 ± 3.1 0.213
2nd wk. 7.1 ± 3.7 4.3 ± 3.3 0.007
4th wk. 6.0 ± 3.9 4.2 ± 3.2 0.077
6th wk. 5.6 ± 4.1 4.1 ± 3.2 0.152
8th wk. 5.6 ± 4.0 4.1 ± 3.2 0.161
P** <0.001 <0.001
P*** 0.045
Score change 5.1 ± 4.0 5.6 ± 3.4 0.656
Data are presented as mean ± SD.
*Independent sample t-Test.
**Repeated measure within group.
***Repeated measure between group.
Table　2　Comparison of each symptom severity score and quality of life from baseline to the end of study in the two groups
BTX-A
n = 25 P*
Cetirizine
n = 25 P*
Before After Before After
Sneezing 2.48 ± 0.87 1.24 ± 1.05 <0.001 2.32 ± 0.80 0.76 ± 0.92 <0.001
Rhinorrhea 2.60 ± 0.64 1.28 ± 1.06 <0.001 2.44 ± 0.58 0.80 ± 1.00 <0.001
Nasal congestion 2.60 ±0.76 1.48 ± 0.87 0.001 1.96 ± 0.73 1.32 ± 0.80 0.004
Nasal itching 1.68 ± 1.10 1.04 ±1.09 0.014 1.92 ± 0.95 0.52 ± 0.77 <0.001
Irritated eye 1.44 ± 0.76 0.60 ± 0.81 <0.001 1.16 ± 0.85 0.76 ± 0.72 0.089
QOL 43.9 ± 14.0 20.1 ± 15.1 <0.001** 28.7 ± 13.1 15.8 ± 11.3 <0.001**
Data are presented as mean ± SD. BTX-A, Botulinum toxin A; QOL, Quality of life.
*Wilcoxon test.
**Paired t-Test.
peated measures analysis showed a significant differ-
ence in symptom severity trend between the two
groups (P = 0.045); however, there was no difference
between the two groups regarding the amount of
change in total symptom severity score (pre-to-post
difference = 5.1 ± 4.0 vs. 5.6 ± 3.4, P = 0.656); Table 1
and Figure 1.
Severity scores of each symptom before and after
the study are presented in Table 2. All symptoms
were significantly improved in both groups, except ir-
ritated eye symptoms in the cetirizine group (P =
0.089). Comparing the two groups regarding the
amount of change revealed a non-significant greater
improvement in nasal congestion (P = 0.06) and more
decrease in eye irritation (P = 0.013) among those
who received BTX-A, and a greater improvement in
nasal itching among those who received cetirizine (P
= 0.019), compared with each of the other group. Be-
cause there was a difference between the two groups
in baseline nasal congestion score (P = 0.002), we
conducted a multivariate analysis. Results showed no
difference between the BTX-A and cetirizine in de-
creasing the severity of nasal congestion (P = 0.742).
Quality of life was improved in both groups (Table
2), but more improvement observed in the BTX-A
group (pre-to-post difference = 23.8 ± 15.6 vs. 12.8 ±
9.3, P = 0.004). Considering the baseline difference
between the two groups in quality of life score (P <
0.001), a multivariate analysis was performed that
showed no difference between the two groups in im-
provement of quality of life (P = 0.300).
In overall, side effects included nasal dryness (4%)
and epistaxis (4%) in the BTX-A group, sleepiness
(44%) and blurred vision (4%) in the cetirizine group.
DISCUSSION
Allergic rhinitis is a common and disturbing disorder
that affects patients’ quality of life. AR causes a great
economic burden on the health care system, there-
fore finding a cost effective treatment for AR is be-
coming increasingly important.14 We compared the
effect of intranasal injection of BTX-A to cetirizine us-
age in the management of AR. Our results demon-
strate that after two months of therapy, the overall se-
verity of rhinitis decreased at the same level when
participants received either BTX-A or cetirizine.
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Symptoms were comparably improved in both
groups, with cetirizine more effective for nasal itching
and BTX-A for irritated eye. The quality of life was
also improved in both groups. Despite the similar ef-
fects of BTX-A and cetirizine on patient symptoms
and quality of life, BTX-A was injected only once and
thus, higher tolerance (compliance) can be achieved
by such treatment. The findings of our study show
that BTX-A causes less frequent irritations and side
effects compared to cetirizine. The epistaxis caused
by BTX-A injection was mild and manageable using
local compression. However, drowsinesssleepiness
occurred in about 50% of the participants receiving
cetirizine, highlighting a better compliance in BTX-A
group. A single dose of BTX-A may seem more ex-
pensive than daily use of cetirizine during two
months of therapy; however side effects and long
term use of antihistamines impose a higher economic
burden with a high costs for indirect expenses due to
patients disability and drowsiness in cetirizine group.
A review by Thorn et al. showed that there is a re-
markable decrease in work productivity among pa-
tients treated with antihistamines such as cetirizine
or loratadine.15 Although our study showed similar ef-
fects of treatments on quality of life, longer follow-ups
are required to investigate if the long-term benefits of
treatment with BTX-A is higher than cetirizine (or
other antihistamines) regarding quality of life and
daily function of the patients.
Mechanisms that explain therapeutic effects of
BTX-A on AR nasal symptoms include anti-
cholinergic and apoptotic signaling. BTX-A has an
anti-cholinergic effect by inhibiting the acetylcholine
release from presynaptic neurons and cholinergic
nerve endings in the sphenopalatine ganglion. It also
induces vasodilatation in nasal vessels that leads to
the blockage of vasoactive intestinal polypeptide.
Additionally, it can cause apoptosis in nasal glands
tissue.16,17 The beneficial effects of BTX-A on rhinitis
have also been shown by previous studies. Rohrbach
et al. used BTX-A sponge (BotoxⓇ) and compared
its effect to saline as a control. Their findings show
that this non-invasive method can reduce the symp-
toms of AR in patients with resistant idiopathic rhini-
tis.10 In a placebo-controlled trial, two units of BTX-A
was injected into the middle turbinate and two units
into the inferior turbinate of each nasal cavity. Results
demonstrated that rhinitis symptoms were signifi-
cantly diminished in BTX-A group compared to the
control.16 Another study showed decrease in vasomo-
tor rhinitis using 10 and 20 IU of BTX-A (BotoxⓇ) in-
jected into the inferior and middle turbinates.18 A re-
cently published study also showed that septal injec-
tion of BTX-A in patients with idiopathic rhinitis could
effectively control the symptoms.19 These studies,
however, did not compare the effect BTX-A with con-
ventional treatments for AR. In this regard, one study
compared the effect of injected BTX-A to ipratropium
bromide nasal spray. Investigators reported that
these two reagents display a similar degree and dura-
tion of efficiency in upper respiratory symptoms.20
Another placebo-controlled trial compared the in-
jected BTX-A (BotoxⓇ) with injected triamcinolone
and found that BTX-A may provide a better treatment
for AR symptoms.11
Uses different doses of BotoxⓇ from 5 to 40 units
for each turbinates10,18,20 as well as routes of applica-
tion (inferior vs. middle turbinate16) and different
methods (injection or applying with sponge) for BTX-
A administration can explain the differences found
between findings of other studies and our results. We
applied 75 IU of a different trade (DysportⓇ) equal to
25-30 units of BotoxⓇ for each turbinate and it seems
that lower doses of BTX-A can be as effective. A well
designed comparative study is required to demon-
strate the minimum effective dose and compare the
invasive vs. non-invasive methods of BTX-A admini-
stration. Another important point is that in some stud-
ies the effect of BTX-A was compared to saline as a
control,11,21 showing a significant improvement in AR
symptoms; however, comparing the effectiveness of
BTX-A with other medications showed equivocal re-
sults indicating that BTX-A may not replace the previ-
ous treatment strategies in uncomplicated cases.
The limitation of our study is a difficulty to conduct
a real double-blinded study by injecting normal saline
in the control group because it is an invasive proce-
dure. Although the two groups were matched in
demographic and baseline clinical variables, they
were differences regarding baseline quality of life
that can be explained by small samples size. We sug-
gest long time follow up of patients to demonstrate
long-term effects of BTX-A injection.
Nasal injection of BTX-A has the same therapeutic
effect as cetirizine in the management of allergic
rhinitis. Since BTX is expensive, we cannot consider
nasal injection of BTX-A as the first lines of allergic
rhinitis management. However, it may be helpful to
use the BTX-A in patients who are resistant to other
treatments or those who have intolerance to current
treatments including nasal corticosteroids or sys-
temic antihistamines. Further studies with longer
follow-ups are required to find long-term effects of
BTX-A injection compared to other medications.
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